Program
Cytarabine
Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.
Drug pageCytarabine: every studyMany companies study it; this page follows only the 32 they lead. All 497 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 30 open or running | phase 3since Oct 4, 2000 | Oct 4, 2000 | none ahead |
| Vion Pharmaceuticalsits history only | 30 open or running | phase 2since Jul 19, 2006 | Jul 8, 2003 | none ahead |
| Antisoma Researchits history only | 20 open or running | phase 3since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 2since Mar 4, 2008 | Mar 4, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 2since Aug 16, 2007 | Aug 16, 2007 | none ahead |
| Moleculin Biotechits history only | 21 open or running | phase 3since Dec 5, 2024 | Feb 22, 2022 | Aug 2029phase 3 · NCT06788756 |
| Theradexits history only | 20 open or running | phase 2since Oct 3, 2003 | Jan 27, 2003 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 18, 2017 | Oct 18, 2017 | none ahead |
| Cornerstone Pharmaceuticalsits history only | 10 open or running | phase 3since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 2since Oct 19, 2021 | Oct 19, 2021 | none ahead |
| Eleosits history only | 10 open or running | phase 2since Dec 19, 2003 | Dec 19, 2003 | none ahead |
| Kanisa Pharmaceuticals | 10 open or running | phase 2since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Kura Oncologyits history only | 11 open or running | phase 3since May 16, 2025 | May 16, 2025 | Nov 2031phase 3 · NCT07007312 |
| Oncovirits history only | 10 open or running | phase 1since Aug 19, 2020 | Aug 19, 2020 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Dec 21, 2017 | Dec 21, 2017 | none ahead |
| Polaris Groupits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 3since Nov 20, 2025 | Nov 20, 2025 | Dec 2027phase 3 · NCT07255872 |
| Stelexis BioSciencesits history only | 11 open or running | phase 1since Jul 24, 2024 | Jul 24, 2024 | Dec 15, 2027phase 1 · NCT06533761 |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Sep 27, 2017 | Sep 27, 2017 | none ahead |
| Tarapeutics Scienceits history only | 11 open or running | phase 2since Jan 16, 2022 | Jan 16, 2022 | none ahead |
| Texas Oncology Cancer Centerits history only | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
| Xanthus Pharmaceuticalsits history only | 10 open or running | phase 2since Jan 5, 2006 | Jan 5, 2006 | none ahead |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kanisa Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2005First study: phase 2 study in Leukemia, MyeloidFirst studyNCT00129168 · 100 enrolled
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Kanisa Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00129168Leukemia, Myeloid | 2 | Completed | Mar 2008 | 100 |
How it is read
Names in the registry
- “Cytarabine”, 15 entries
- “cytarabine”, 8 entries
- “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
- “Cytarabine (Ara-C)”, 1 entry
- “Eganelisib in combination with cytarabine”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 22 studies
- Leukemia, 3 studies
- Lymphoma, 2 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.